Abstract The primary treatment for non-metastatic colorectal cancer is surgical resection. Despite the use of neoadjuvant and/or adjuvant chemoradiation, up to 30% of patients undergoing surgery for colorectal cancer will develop a postoperative recurrence. Why patients develop postoperative tumors despite all known cancer being resected at the time of surgery is largely unknown, and novel biomarkers that can predict the development of recurrence are lacking.
We help organisations harness PR and social media to listen, engage and manage the conversations that matter.
Get in touch with Sara
Contact Sara, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack